3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
3
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Multiple Myeloma
1
Melanoma
1
Male Urogenital Diseases
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Interventions
padeliporfin
5
Nivolumab
5
Ipilimumab
4
Sunitinib
3
Specimen Handling
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Abiraterone Acetate
3
pembrolizumab
2
motexafin gadolinium
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
abiraterone
2
Surveys and Questionnaires
2
Radiation Dose Hypofractionation
2
Pluvicto
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
CTLA-4 Antigen
2
vinflunine
1
valrubicin
1
tislelizumab
1
temsirolimus
1
sipuleucel-T
1
relatlimab
1
palladium-bacteriopheophorbide
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
relatlimab
×
Genitourinary
×
Clear all
NCT06237920
2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2
Recruiting
90 enrolled